Nasdaq submits key 19b-4 filing for Grayscale's Hedera ETF
Quick Take Nasdaq filed a 19b-4 on behalf of Grayscale’s spot Hedera ETF on Monday. Bloomberg Analyst Eric Balchunas previously said Hedera and Litecoin ETF applications have the “best odds” of approval.
The Nasdaq Stock Market LLC filed a 19b-4 form with the U.S. Securities and Exchange Commission on Monday to list and trade Grayscale's spot Hedera (HBAR) exchange-traded fund.
A 19b-4 filing is the second part of a two-step process for proposing a crypto ETF to the SEC. Once acknowledged by the SEC, the filing will be published in the Federal Register, initiating the agency's approval process.
The filing on behalf of Grayscale comes a week after the Nasdaq submitted a 19b-4 for Canary Capital's spot HBAR ETF . Last week, Bloomberg Senior ETF Analyst Eric Balchunas said that Hedera and Litecoin have the "best odds and the pole position" among altcoin ETF filings, given the level of progress they have had with the SEC.
Hedera is a decentralized public network that uses the Hashgraph consensus algorithm to facilitate transactions. The Hedera token is governed by a council composed of prominent companies and organizations such as Google and IBM, responsible for decision-making and token distribution.
Hedera traded down 14.5% over the past 24 hours at $0.22, according to The Block's HBAR price page .
Since the reelection of Donald Trump, the U.S. has seen a flurry of new crypto ETF filings based on tokens beyond bitcoin and ether. With hopes that the now crypto-positive SEC would hand out approvals, U.S. issuers have filed spot ETF applications for Solana, XRP, Cardano, Litecoin and Dogecoin.
Earlier today, the New York Stock Exchange filed a 19b-4 on behalf of Bitwise's Dogecoin ETF. Bloomberg analysts predicted last month that Dogecoin ETFs have a 75% chance of approval from the SEC.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Banks retreat, bond discounts, and it's hard to borrow money for the AI construction boom
Discounted sales of high-yield bonds have become the new norm—among this year's $55 billion related bonds, the most recent four issuances were all at a discount; major banks such as Société Générale and Mitsubishi are adopting a more cautious approach; Oracle's force majeure event has further prompted lenders to tighten their terms. With $700 billion in capital expenditures from mega-tech companies competing for financing, combined with rising Treasury yields, the cost of funding for some projects is approaching the break-even point. Developers with lower ratings and less experience are being hit first.
Trading congestion! Bank of America warns: "Buy AI, sell consumer" strategies are increasingly difficult to generate excess returns
Active fund holdings have already fully reflected the theme of "consumption shifting to capital expenditure." It is becoming increasingly difficult to generate excess returns by buying beneficiaries of AI capital expenditure and selling white-collar consumption themes.
Replica of the "Semiconductor Moment": The "Bottleneck Trade" in AI Drug Discovery Is Taking Shape—Who Will Be the Next "Shovel Seller"?
Investor Freda Duan pointed out that AI-driven drug development is shaping structural opportunities similar to "bottleneck trades" in the semiconductor industry. The core logic is that AI turns failed experiments into valuable training data, and wet laboratories are transforming from "medicine making" to "data creation." DNA synthesis, protein production, and CROs may become the earliest beneficiaries as the "pick-and-shovel sellers."
Crypto prices
More
